Herlyn MM - Search Results

1

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA. Kim H, et al. Among authors: herlyn mm. Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28. Cell Rep. 2015. PMID: 26027934 Free PMC article.

2

BRAF as a potential therapeutic target in melanoma and other malignancies.

Tuveson DA, Weber BL, Herlyn M. Tuveson DA, et al. Cancer Cell. 2003 Aug;4(2):95-8. doi: 10.1016/s1535-6108(03)00189-2. Cancer Cell. 2003. PMID: 12957284 Free article. Review. No abstract available.

3

Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics.

Smalley KS, Herlyn M. Smalley KS, et al. Ann N Y Acad Sci. 2005 Nov;1059:16-25. doi: 10.1196/annals.1339.005. Ann N Y Acad Sci. 2005. PMID: 16382039 Review.

4

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.

Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Smalley KS, et al. Mol Cancer Ther. 2006 May;5(5):1136-44. doi: 10.1158/1535-7163.MCT-06-0084. Mol Cancer Ther. 2006. PMID: 16731745

5

Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.

Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Hoek KS, et al. Pigment Cell Res. 2006 Aug;19(4):290-302. doi: 10.1111/j.1600-0749.2006.00322.x. Pigment Cell Res. 2006. PMID: 16827748

6

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

Smalley KS, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS, Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. Smalley KS, et al. Cancer Res. 2007 Jan 1;67(1):209-17. doi: 10.1158/0008-5472.CAN-06-1538. Cancer Res. 2007. PMID: 17210701

7

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M. Smalley KS, et al. Br J Cancer. 2007 Feb 12;96(3):445-9. doi: 10.1038/sj.bjc.6603596. Epub 2007 Jan 23. Br J Cancer. 2007. PMID: 17245336 Free PMC article.

8

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X. Kumar SM, et al. Cancer Res. 2007 Apr 1;67(7):3177-84. doi: 10.1158/0008-5472.CAN-06-3312. Cancer Res. 2007. PMID: 17409425

9

Rewired ERK-JNK signaling pathways in melanoma.

Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. Lopez-Bergami P, et al. Cancer Cell. 2007 May;11(5):447-60. doi: 10.1016/j.ccr.2007.03.009. Cancer Cell. 2007. PMID: 17482134 Free PMC article.

10

Roadmap for new opportunities in melanoma research.

Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D. Herlyn M, et al. Semin Oncol. 2007 Dec;34(6):566-76. doi: 10.1053/j.seminoncol.2007.09.004. Semin Oncol. 2007. PMID: 18083380

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

621 results

Search Page

Filters